Elpiscience Biopharmaceuticals

Elpiscience Biopharmaceuticals company information, Employees & Contact Information

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.
Looking for a particular Elpiscience Biopharmaceuticals employee's phone or email?

Elpiscience Biopharmaceuticals Questions

News

Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager - PR Newswire

Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager PR Newswire

Elpiscience to Present Its Novel Immunotherapies at Biotech Showcase™ during J.P. Morgan Week 2023 - Business Wire

Elpiscience to Present Its Novel Immunotherapies at Biotech Showcase™ during J.P. Morgan Week 2023 Business Wire

Elpiscience and Astellas partner for new macrophage engagers - Pharmaceutical Technology

Elpiscience and Astellas partner for new macrophage engagers Pharmaceutical Technology

Elpiscience Announces Studies Presented at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting - The AI Journal

Elpiscience Announces Studies Presented at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting The AI Journal

Astellas strikes $1.7bn SIRP drug deal with Elpiscience - pharmaphorum

Astellas strikes $1.7bn SIRP drug deal with Elpiscience pharmaphorum

Elpiscience, Astellas Partner on Novel Bispecific Macrophage Engager - Contract Pharma

Elpiscience, Astellas Partner on Novel Bispecific Macrophage Engager Contract Pharma

TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGF - PR Newswire

TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGF PR Newswire

Elpiscience gets $35m in series A-plus - - Global Venturing

Elpiscience gets $35m in series A-plus - Global Venturing

ES-019, a PD-L1/SIRPα bispecific macrophage engager, shows antitumor efficacy in vivo - BioWorld MedTech

ES-019, a PD-L1/SIRPα bispecific macrophage engager, shows antitumor efficacy in vivo BioWorld MedTech

Kelun Pharmaceutical-B has submitted an IPO prospectus and plans to list on the Hong Kong Stock Exchange, exclusively sponsored by CITIC Securities. - 富途牛牛

Kelun Pharmaceutical-B has submitted an IPO prospectus and plans to list on the Hong Kong Stock Exchange, exclusively sponsored by CITIC Securities. 富途牛牛

Top Elpiscience Biopharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant